Emergent BioSolutions (NYSE:EBS) Given “Buy” Rating at HC Wainwright

Emergent BioSolutions (NYSE:EBS)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $15.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 118.98% from the stock’s current price.

EBS has been the subject of several other reports. Benchmark lifted their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. StockNews.com upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Monday, February 17th.

Emergent BioSolutions Price Performance

Shares of NYSE EBS opened at $6.85 on Tuesday. Emergent BioSolutions has a fifty-two week low of $1.82 and a fifty-two week high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The company has a market capitalization of $371.16 million, a price-to-earnings ratio of -1.67 and a beta of 1.62. The company has a 50 day simple moving average of $9.52 and a two-hundred day simple moving average of $9.08.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The business had revenue of $194.70 million during the quarter, compared to analyst estimates of $254.67 million. During the same period last year, the business earned ($0.77) EPS. Analysts expect that Emergent BioSolutions will post -0.63 EPS for the current fiscal year.

Institutional Trading of Emergent BioSolutions

A number of hedge funds have recently bought and sold shares of the company. Covestor Ltd grew its stake in shares of Emergent BioSolutions by 5,458.5% during the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 2,893 shares during the period. Northern Trust Corp boosted its holdings in shares of Emergent BioSolutions by 2.6% in the fourth quarter. Northern Trust Corp now owns 145,889 shares of the biopharmaceutical company’s stock worth $1,395,000 after buying an additional 3,692 shares during the last quarter. LPL Financial LLC grew its position in Emergent BioSolutions by 34.5% during the fourth quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 3,875 shares during the period. Federated Hermes Inc. increased its holdings in Emergent BioSolutions by 2.2% during the fourth quarter. Federated Hermes Inc. now owns 277,810 shares of the biopharmaceutical company’s stock valued at $2,656,000 after buying an additional 6,058 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in Emergent BioSolutions during the fourth quarter valued at approximately $63,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.